Tamoxifen decreases ovarian toxicity without compromising cancer treatment in a rat model of mammary cancer
Authors:
Open Access
- 13 June 2023
- journal article
- research article
- Published by Springer Nature in BMC Genomics
- Vol. 24 (1) , 1-15
Abstract
Background: Premenopausal women diagnosed with breast cancer often face aggressive chemotherapy resulting in infertility. Tamoxifen (TAM) is a selective estrogen receptor modulator that was previously suggested as a protective agent against chemotherapy-induced ovarian failure. In the current study, we examined mechanisms of the protective action of TAM in the ovaries of tumor-bearing rats treated with the chemotherapy drug cyclophosphamide (CPA).Results: TAM prevented CPA-induced loss of ovarian follicular reserves. The protective TAM effect in the rat ovary partially resulted from decreased apoptosis. In addition, transcriptomic and proteomic screening also implicated the importance of DNA repair pathways as well as cell adhesion and extracellular matrix remodeling in the protective ovarian actions of TAM.Conclusions: Tamoxifen shielded the ovary from the side effects of chemotherapy without lessening the tumoricidal actions of mammary cancer treatment.GraphicalKeywords
Funding Information
- National Science Center (2016/21/B/NZ4/00202)
This publication has 68 references indexed in Scilit:
- Pathview: an R/Bioconductor package for pathway-based data integration and visualizationBioinformatics, 2013
- Estrogen receptor signaling as a target for novel breast cancer therapeuticsBiochemical Pharmacology, 2013
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Hormonal therapy in breast cancer: A model disease for the personalization of cancer careMolecular Oncology, 2012
- Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivationMolecular Cancer, 2011
- Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the ratJournal of Assisted Reproduction and Genetics, 2010
- Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarityOncogene, 2009
- Increased expression of the integral membrane protein ErbB2 in Chinese hamster ovary cells expressing the anti-apoptotic gene Bcl-xLProtein Expression and Purification, 2009
- Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRtNature Protocols, 2009
- Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosisInternational Journal of Cancer, 2008